Empagliflozin
Based on 96 publication(s) in Google Scholar
Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC50 of 3.1 nM for human SGLT-2.
For research use only. We do not sell to patients.
- Purity: 99.90%
- CAS No.: 864070-44-0
- Formula: C23H27ClO7
- Molecular Weight:450.91
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Immunology/Inflammation Compound Library
HY-L007
-
Membrane Transporter/Ion Channel Compound Library
HY-L011
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
Drug Repurposing Compound Library
HY-L035
-
Anti-diabetic Compound Library
HY-L040
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Anti-COVID-19 Compound Library
HY-L052
-
NMPA-Approved Drug Library
HY-L053
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Anti-Obesity Compound Library
HY-L087
-
Rare Diseases Drug Library
HY-L102
-
Pediatric Drug Library
HY-L104
-
EMA-Approved Drug Library
HY-L116
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Non-steroidal Anti-Inflammatory Compound Library
HY-L130
-
Heterocyclic Compound Library
HY-L138
-
Off-patent Drug Library
HY-L141
-
Mitochondrial Protection Compound Library
HY-L144
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Highly Selective Inhibitors Library
HY-L158
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Nephrotoxicity Compound Library
HY-L229
-
RNA Binding Bioactive Compound Library
HY-L248
-
Classic FDA-Approved Drug Library
HY-L261
Publications Citing Use of MedChemExpress (MCE) Empagliflozin
More- Cell. 2025 Sep 18;188(19):5142-5156.e23. [Abstract]
- Nat Commun. 2025 Dec 19. [Abstract]
- Nat Commun. 2025 Nov 25;16(1):10430. [Abstract]
- Protein Cell. 2022 May;13(5):336-359. [Abstract]
- Redox Biol. 2026 Jul:94:104228. [Abstract]
- Metabolism. 2023 Sep:146:155657. [Abstract]
- Cell Rep Med. 2025 Dec 16;6(12):102507. [Abstract]
- Cardiovasc Diabetol. 2024 Jul 23;23(1):269. [Abstract]
- Cardiovasc Diabetol. 2023 Feb 6;22(1):27. [Abstract]
- Diabetologia. 2017 Mar;60(3):568-573. [Abstract]
- Acta Biomater. 2022 Apr 1:142:99-112. [Abstract]
- Cell Commun Signal. 2024 Nov 7;22(1):534. [Abstract]
- Circ Heart Fail. 2020 Jan;13(1):e006277. [Abstract]
- Free Radic Biol Med. 2023 Feb 1:195:89-102. [Abstract]
- Basic Res Cardiol. 2024 Oct;119(5):751-772. [Abstract]
- Basic Res Cardiol. 2022 Sep 28;117(1):47. [Abstract]
- Br J Pharmacol. 2025 Jul 11. [Abstract]
- Br J Pharmacol. 2024 Nov;181(21):4294-4310. [Abstract]
- Biomed Pharmacother. 2024 Jun 27:177:117044. [Abstract]
- Biomed Pharmacother. 2024 May:174:116477. [Abstract]
- Biomed Pharmacother. 2023 Aug:164:114907. [Abstract]
- JACC Basic Transl Sci. 2019 Sep 4;4(5):575-591. [Abstract]
- JACC Basic Transl Sci. 2017 Aug 4;2(4):347-354. [Abstract]
- Cell Rep. 2023 Sep 25;42(10):113174. [Abstract]
- Antioxidants (Basel). 2022 Apr 19;11(5):799. [Abstract]
- Biochem Pharmacol. 2026 Jun 12;251(Pt 2):118159. [Abstract]
- Biochem Pharmacol. 2025 Aug 22;242(Pt 1):117277. [Abstract]
- Biochem Pharmacol. 2025 May:235:116821. [Abstract]
- Biochem Pharmacol. 2018 Jun:152:45-59. [Abstract]
- Geroscience. 2024 Oct;46(5):4969-4986. [Abstract]
- J Am Heart Assoc. 2026 Feb 17;15(4):e043917. [Abstract]
- J Am Heart Assoc. 2022 Feb 15;11(4):e023800. [Abstract]
- Life Sci. 2019 Sep 1:232:116622. [Abstract]
- Int J Mol Sci. 2026 May 21;27(10):4641. [Abstract]
- Int J Mol Sci. 2025 Oct 16;26(20):10098. [Abstract]
- Int J Mol Sci. 2024 Jul 10;25(14):7567. [Abstract]
- Int J Mol Sci. 2021 Jan 15;22(2):818. [Abstract]
- Biomolecules. 2022 Aug 25;12(9):1176. [Abstract]
- Front Pharmacol. 2022 Mar 23:13:826792. [Abstract]
- Front Pharmacol. 2021 Apr 29:12:664181. [Abstract]
- Int Immunopharmacol. 2025 Sep 6:165:115508. [Abstract]
- Eur J Pharm Sci. 2021 Jun 1:161:105788. [Abstract]
- FASEB J. 2024 Jul 31;38(14):e23816. [Abstract]
- Bioengineered. 2021 Dec;12(2):9356-9366. [Abstract]
- Lipids Health Dis. 2021 Jan 12;20(1):5. [Abstract]
- J Inflamm Res. 2021 May 31:14:2277-2287. [Abstract]
- Sci Rep. 2025 Mar 15;15(1):8986. [Abstract]
- Sci Rep. 2024 Dec 28;14(1):30764. [Abstract]
- Am J Pathol. 2025 Dec 13:S0002-9440(25)00433-X. [Abstract]
- Am J Pathol. 2023 Jan;193(1):121-133. [Abstract]
- Mol Cell Endocrinol. 2019 Aug 20:494:110487. [Abstract]
- Vascul Pharmacol. 2023 Oct:152:107212. [Abstract]
- Vascul Pharmacol. 2018 Oct:109:56-71. [Abstract]
- Saudi Pharm J. 2026 Jan 13;34(1):4. [Abstract]
- Am J Physiol Renal Physiol. 2021 Aug 1;321(2):F149-F161. [Abstract]
- Am J Physiol Gastrointest Liver Physiol. 2024 Aug 1;327(2):G235-G253. [Abstract]
- Int J Cardiol. 2026 Feb 27:134266. [Abstract]
- Cardiooncology. 2025 Nov 13;11(1):106. [Abstract]
- J Physiol Sci. 2024 Sep 28;74(1):48. [Abstract]
- J Physiol Sci. 2023 Sep 13;73(1):20. [Abstract]
- J Physiol Sci. 2023 Apr 12;73(1):7. [Abstract]
- Int J Med Sci. 2018 Jun 13;15(9):937-943. [Abstract]
- Folia Microbiol (Praha). 2026 Jun 3. [Abstract]
- J Diabetes Complications. 2025 Jan 18;39(2):108952. [Abstract]
- Intensive Care Med Exp. 2024 Jul 8;12(1):64. [Abstract]
- Cardiovasc Drugs Ther. 2022 Aug;36(4):619-632. [Abstract]
- Int J Cardiol Cardiovasc Risk Prev. 2026 Apr 7:29:200632. [Abstract]
- Mol Immunol. 2024 Mar:167:43-52. [Abstract]
- Ren Fail. 2022 Dec;44(1):1528-1542. [Abstract]
- Diabetes Metab Syndr Obes. 2021 Jan 18:14:227-240. [Abstract]
- Diabetes Metab Syndr Obes. 2020 Jun 12;13:1953-1967. [Abstract]
- J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Aug 1:1027:227-33. [Abstract]
- J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Sep 1;1000:22-8. [Abstract]
- Arch Microbiol. 2026 May 20;208(8):396. [Abstract]
- BMC Cardiovasc Disord. 2025 Jun 7;25(1):437. [Abstract]
- Biochem Biophys Res Commun. 2024 Oct 28:737:150912. [Abstract]
- Cell Physiol Biochem. 2019;53(5):865-886. [Abstract]
- Physiol Rep. 2025 Dec;13(23):e70653. [Abstract]
- Biomed Chromatogr. 2019 Nov;33(11):e4663. [Abstract]
- Biomed Chromatogr. 2016 Oct;30(10):1549-55. [Abstract]
- Preprints. 2026 Apr 21.
- bioRxiv. 2026 Mar 14.
- bioRxiv. 2026 Feb 3.
- bioRxiv. 2025 Sep 23:2025.09.12.675896. [Abstract]
- Res Sq. 2025 Aug 11.
- Technische Universitat Dresden. 2025.
- bioRxiv. 2025 May 19.
- University of Antwerp. 2025.
- Res Sq. 2024 Aug 20.
- bioRxiv. 2024 Sep 23:2024.09.23.614368. [Abstract]
- SSRN. 2023 May 18.
- Annals of the Romanian Society for Cell Biology. 2021 Mar 15.
- Research Square Preprint. 2021 Feb.
- European Journal of Molecular & Clinical Medicine. 2020, 7(1): 4324-4334.
- University of Alberta. 2019 Dec.
- McGill University. 2018 Jan.
Customer Validation & Images
-
In Vivo Efficacy Study
-
WB
-
IF
-
WB
-
Cell Proliferation/Viability Assay
Biological Activity
|
SGLT2 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | EC50 |
0.003 μM
Compound: 155
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability by MTT assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability by MTT assay
|
[PMID: 38295689] |
Empagliflozin is a potent and competitive SGLT-2 inhibitor with an excellent selectivity profile and the highest selectivity window of the tested SGLT-2 inhibitors over hSGLT-1. Empagliflozin inhibits the uptake of [14C]-alpha-methyl glucopyranoside (AMG) via hSGLT-2 in a dose-dependent manner with an IC50 of 3.1 nM, but is less potent for other SGLTs (IC50 range: 1100-11000 nM). [3H]-Empagliflozin displays a high affinity for SGLT-2 with a mean Kd of 57±37 nM in the absence of glucose in kinetic binding experiments[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 864070-44-0
-
Appearance Solid
-
Molecular Weight 450.91
-
Formula C23H27ClO7
-
Color White to off-white
-
SMILES
ClC(C=CC([C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)=C2)=C2CC(C=C3)=CC=C3O[C@H]4CCOC4
-
Synonyms
BI 10773
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (96)
-
Journal Impact Factor
-
Most Recent
-
Cell
2025 Sep 18;188(19):5142-5156.e23. PMID: 40555230
Empagliflozin purchased from MedChemExpress. Usage Cited in: Cell. 2025 Sep 18;188(19):5142-5156.e23. [Abstract]
DIO mice were treated with empagliflozin (10 mg/kg), compound 15 (1 mg/kg), or both empagliflozin and compound 15 by daily oral gavage for 3 weeks, and blood glucose levels were monitored following fasting and after glucose administration (2.5 g/kg lean mass).
Empagliflozin purchased from MedChemExpress. Usage Cited in: Cell. 2025 Sep 18;188(19):5142-5156.e23. [Abstract]
Western blot analysis of IDH2-K272 lactylation levels in infarct border zone tissues of IDH2WT and IDH2EC-K272R mice following induction of myocardial infarction (MI) or DMI with gavage administration of EMPA (i.g. 30 mg/kg/day, 7 days; n = 6).
Empagliflozin purchased from MedChemExpress. Usage Cited in: Cell. 2025 Sep 18;188(19):5142-5156.e23. [Abstract]
Representative Immunofluorescence staining of IDH2-K272la in heart from IDH2WT and IDH2EC-K272R mice following induction of MI or DMI with empagliflozin (i.g. 30 mg/kg/day, 7 days).
-
Nat Commun
IDH2 lactylation promotes angiogenesis in murine diabetic myocardial infarction via blocking Cav1-eNOS interaction. [Abstract]2025 Dec 19. PMID: 41419771 -
Nat Commun
FGF4-FGFR1 signaling promotes podocyte survival and glomerular function to ameliorate diabetic kidney disease in male mice. [Abstract]2025 Nov 25;16(1):10430. PMID: 41290710 -
Protein Cell
Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis. [Abstract]2022 May;13(5):336-359. PMID: 33417139 -
Redox Biol
Advanced glycation end-products exacerbate myocardial ischemia/reperfusion injury by promoting mitochondrial oxidative damage and PANoptosis in diabetes mellitus. [Abstract]2026 Jul:94:104228. PMID: 42176503 -
Metabolism
SGLT2 inhibitor empagliflozin downregulates miRNA-34a-5p and targets GREM2 to inactivate hepatic stellate cells and ameliorate non-alcoholic fatty liver disease-associated fibrosis. [Abstract]2023 Sep:146:155657. PMID: 37422021 -
Cell Rep Med
Targeting long-chain acylcarnitine accumulation to protect cardiac mitochondrial homeostasis after complete revascularization. [Abstract]2025 Dec 16;6(12):102507. PMID: 41406945 -
Cardiovasc Diabetol
Empagliflozin protects against heart failure with preserved ejection fraction partly by inhibiting the senescence-associated STAT1-STING axis. [Abstract]2024 Jul 23;23(1):269. PMID: 39044275 -
Cardiovasc Diabetol
Empagliflozin suppressed cardiac fibrogenesis through sodium-hydrogen exchanger inhibition and modulation of the calcium homeostasis. [Abstract]2023 Feb 6;22(1):27. PMID: 36747205 -
Diabetologia
Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits. [Abstract]2017 Mar;60(3):568-573. PMID: 27752710 -
Acta Biomater
Core fucosylation involvement in the paracrine regulation of proteinuria-induced renal interstitial fibrosis evaluated with the use of a microfluidic chip. [Abstract]2022 Apr 1:142:99-112. PMID: 35189379 -
Cell Commun Signal
Inhibition of SGLT2 protects podocytes in diabetic kidney disease by rebalancing mitochondria-associated endoplasmic reticulum membranes. [Abstract]2024 Nov 7;22(1):534. PMID: 39511548 -
Circ Heart Fail
Empagliflozin Blunts Worsening Cardiac Dysfunction Associated With Reduced NLRP3 (Nucleotide-Binding Domain-Like Receptor Protein 3) Inflammasome Activation in Heart Failure. [Abstract]2020 Jan;13(1):e006277. PMID: 31957470 -
Free Radic Biol Med
Empagliflozin attenuates the renal tubular ferroptosis in diabetic kidney disease through AMPK/NRF2 pathway. [Abstract]2023 Feb 1:195:89-102. PMID: 36581059 -
Basic Res Cardiol
Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2. [Abstract]2024 Oct;119(5):751-772. PMID: 39046464 -
Basic Res Cardiol
Bone marrow-derived naïve B lymphocytes improve heart function after myocardial infarction: a novel cardioprotective mechanism for empagliflozin. [Abstract]2022 Sep 28;117(1):47. PMID: 36171393 -
Br J Pharmacol
Blockade of cannabinoid CB1 receptors potentiates the anti-fibrotic effects mediated by SGLT2 inhibition in a mouse model of diabetic nephropathy. [Abstract]2025 Jul 11. PMID: 40650347 -
Br J Pharmacol
Adjunctive therapy with an oral H2S donor provides additional therapeutic benefit beyond SGLT2 inhibition in cardiometabolic heart failure with preserved ejection fraction. [Abstract]2024 Nov;181(21):4294-4310. PMID: 38982742 -
Biomed Pharmacother
Xelaglifam, a novel GPR40/FFAR1 agonist, exhibits enhanced β-arrestin recruitment and sustained glycemic control for type 2 diabetes. [Abstract]2024 Jun 27:177:117044. PMID: 38941892 -
Biomed Pharmacother
2024 May:174:116477. PMID: 38522235 -
Biomed Pharmacother
Canagliflozin mitigates carfilzomib-induced endothelial apoptosis via an AMPK-dependent pathway. [Abstract]2023 Aug:164:114907. PMID: 37247463 -
JACC Basic Transl Sci
Cardiac Microvascular Endothelial Enhancement of Cardiomyocyte Function Is Impaired by Inflammation and Restored by Empagliflozin. [Abstract]2019 Sep 4;4(5):575-591. PMID: 31768475 -
JACC Basic Transl Sci
Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure. [Abstract]2017 Aug 4;2(4):347-354. PMID: 30062155
Empagliflozin purchased from MedChemExpress. Usage Cited in: JACC Basic Transl Sci. 2017 Aug 4;2(4):347-354. [Abstract]
Improved In Vivo Cardiac Function in Empagliflozin-Treated Mice With Heart Failure Is PreservedEx Vivo. Hearts from vehicle- and Empa-treated mice with HF are perfused ex vivo to measure cardiac function. Cardiac output (A) and cardiac work (B) are measured using ex vivo perfused working hearts.
-
Cell Rep
A transient wave of Bhlhe41+ resident macrophages enables remodeling of the developing infarcted myocardium. [Abstract]2023 Sep 25;42(10):113174. PMID: 37751357 -
Antioxidants (Basel)
Empagliflozin-Enhanced Antioxidant Defense Attenuates Lipotoxicity and Protects Hepatocytes by Promoting FoxO3a- and Nrf2-Mediated Nuclear Translocation via the CAMKK2/AMPK Pathway. [Abstract]2022 Apr 19;11(5):799. PMID: 35624663 -
Biochem Pharmacol
Aquaporin-1 (AQP1) mediates cardiac oedema and mitochondrial dysfunction in cardiometabolic HFpEF: New insights into the mechanisms of SGLT2 inhibitors. [Abstract]2026 Jun 12;251(Pt 2):118159. PMID: 42285370 -
Biochem Pharmacol
Empagliflozin alleviates doxorubicin-induced myocardial injury by inhibiting RIP3-dependent TLR4/MyD88/NF-κB signaling pathway. [Abstract]2025 Aug 22;242(Pt 1):117277. PMID: 40850356 -
Biochem Pharmacol
Empagliflozin attenuates renal damage in diabetic nephropathy by modulating mitochondrial quality control via Prdx3-PINK1 pathway. [Abstract]2025 May:235:116821. PMID: 39983849 -
Biochem Pharmacol
Canagliflozin exerts anti-inflammatory effects by inhibiting intracellular glucose metabolism and promoting autophagy in immune cells. [Abstract]2018 Jun:152:45-59. PMID: 29551587
Empagliflozin purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2018 Jun:152:45-59. [Abstract]
Effects of BMS-512148 and Empagliflozin on p62 expression in LPS-untreated and LPS-treated RAW264.7 cells.
-
Geroscience
2024 Oct;46(5):4969-4986. PMID: 38922380 -
J Am Heart Assoc
Empagliflozin Attenuates Cardiac Fibrosis by Suppressing Fibroblast-Mediated C-C Motif Chemokine Ligand 2 Expression. [Abstract]2026 Feb 17;15(4):e043917. PMID: 41669956 -
J Am Heart Assoc
HMGB1-Promoted Neutrophil Extracellular Traps Contribute to Cardiac Diastolic Dysfunction in Mice. [Abstract]2022 Feb 15;11(4):e023800. PMID: 35156391 -
Life Sci
Therapy of empagliflozin plus metformin on T2DM mice shows no higher amelioration for glucose and lipid metabolism than empagliflozin monotherapy. [Abstract]2019 Sep 1:232:116622. PMID: 31271767 -
Int J Mol Sci
Investigating the Effects and Potential Mechanisms of Astragalus Root Against Diabetic Nephropathy Based on Bioinformatics Analysis and In Vitro Validation. [Abstract]2026 May 21;27(10):4641. PMID: 42196627 -
Int J Mol Sci
Comparison of the Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cardiac Fibroblast Properties. [Abstract]2025 Oct 16;26(20):10098. PMID: 41155391 -
Int J Mol Sci
SGLT2 Inhibitors Empagliflozin and Canagliflozin Ameliorate Allergic Asthma Responses in Mice. [Abstract]2024 Jul 10;25(14):7567. PMID: 39062810 -
Int J Mol Sci
Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE(-/-) Mice by Activating Autophagy and Reducing ER Stress and Apoptosis. [Abstract]2021 Jan 15;22(2):818. PMID: 33467546 -
Biomolecules
Renal Metabolome in Obese Mice Treated with Empagliflozin Suggests a Reduction in Cellular Respiration. [Abstract]2022 Aug 25;12(9):1176. PMID: 36139016 -
Front Pharmacol
Empagliflozin Ameliorates Preeclampsia and Reduces Postpartum Susceptibility to Adriamycin in a Mouse Model Induced by Angiotensin Receptor Agonistic Autoantibodies. [Abstract]2022 Mar 23:13:826792. PMID: 35401209 -
Front Pharmacol
Sodium-Glucose CoTransporter-2 Inhibitor Empagliflozin Ameliorates Sunitinib-Induced Cardiac Dysfunction via Regulation of AMPK-mTOR Signaling Pathway-Mediated Autophagy. [Abstract]2021 Apr 29:12:664181. PMID: 33995090 -
Int Immunopharmacol
Empagliflozin alleviates hepatic ischemia-reperfusion injury by inhibiting c-Myc through the JAK1-STAT3 signaling pathway. [Abstract]2025 Sep 6:165:115508. PMID: 40915190 -
Eur J Pharm Sci
Empagliflozin prevents from early cardiac injury post myocardial infarction in non-diabetic mice. [Abstract]2021 Jun 1:161:105788. PMID: 33684486 -
FASEB J
Empagliflozin impact on experimentally induced acetaminophen toxicity: Imprint of mitochondrial dynamics, biogenesis, and cGAS/STING signal in amending liver insult. [Abstract]2024 Jul 31;38(14):e23816. PMID: 39072779 -
Bioengineered
Empagliflozin protects diabetic pancreatic tissue from damage by inhibiting the activation of the NLRP3/caspase-1/GSDMD pathway in pancreatic β cells: in vitro and in vivo studies. [Abstract]2021 Dec;12(2):9356-9366. PMID: 34823419 -
Lipids Health Dis
Empagliflozin protects against atherosclerosis progression by modulating lipid profiles and sympathetic activity. [Abstract]2021 Jan 12;20(1):5. PMID: 33436015 -
J Inflamm Res
Empagliflozin Alleviates Atherosclerosis Progression by Inhibiting Inflammation and Sympathetic Activity in a Normoglycemic Mouse Model. [Abstract]2021 May 31:14:2277-2287. PMID: 34103961 -
Sci Rep
Empagliflozin demonstrates neuroprotective and cardioprotective effects by reducing ischemia/reperfusion damage in rat models of ischemic stroke and myocardial infarction. [Abstract]2025 Mar 15;15(1):8986. PMID: 40089564 -
Sci Rep
Effects of Empagliflozin and Dapagliflozin in alleviating cardiac fibrosis through SIRT6-mediated oxidative stress reduction. [Abstract]2024 Dec 28;14(1):30764. PMID: 39730461 -
Am J Pathol
Targeting Skeletal Muscle in Duchenne Muscular Dystrophy: Integrating in Silico and Experimental Approaches to Sodium-Glucose Cotransporter-2 Inhibition. [Abstract]2025 Dec 13:S0002-9440(25)00433-X. PMID: 41391749 -
Am J Pathol
The Effects of Hyperglycemia on Early Endothelial Activation and the Initiation of Atherosclerosis. [Abstract]2023 Jan;193(1):121-133. PMID: 36243046 -
Mol Cell Endocrinol
Empagliflozin improves primary haemodynamic parameters and attenuates the development of atherosclerosis in high fat diet fed APOE knockout mice. [Abstract]2019 Aug 20:494:110487. PMID: 31195080 -
Vascul Pharmacol
Empagliflozin decreases ageing-associated arterial stiffnening and decreases vascular fibrosis under normoglycemic conditions. [Abstract]2023 Oct:152:107212. PMID: 37619798 -
Vascul Pharmacol
Hyperglycaemic impairment of PAR2-mediated vasodilation: Prevention by inhibition of aortic endothelial sodium-glucose-co-Transporter-2 and minimizing oxidative stress. [Abstract]2018 Oct:109:56-71. PMID: 29908295 -
Saudi Pharm J
Empagliflozin improves renal injury of diabetic nephropathy complicated with hyperuricemia through AMPK by promoting autophagy and inhibiting apoptosis. [Abstract]2026 Jan 13;34(1):4. PMID: 41528619 -
Am J Physiol Renal Physiol
Therapeutic effects of lisinopril and empagliflozin in a mouse model of hypertension-accelerated diabetic kidney disease. [Abstract]2021 Aug 1;321(2):F149-F161. PMID: 34180715 -
Am J Physiol Gastrointest Liver Physiol
SGLT2 inhibition leads to a restoration of hepatic and circulating metabolites involved in the folate cycle and pyrimidine biosynthesis. [Abstract]2024 Aug 1;327(2):G235-G253. PMID: 38915277 -
Int J Cardiol
Early development and SGLT2 inhibitor-mediated reversal of coronary microvascular dysfunction in an isoprenaline-induced murine HFpEF model: Insights from multimodal in vivo imaging. [Abstract]2026 Feb 27:134266. PMID: 41765145 -
Cardiooncology
Breast cancer progression in the presence of treated and untreated left ventricular dysfunction. [Abstract]2025 Nov 13;11(1):106. PMID: 41233850 -
J Physiol Sci
Acute effects of empagliflozin on open-loop baroreflex function and urine output in streptozotocin-induced type 1 diabetic rats. [Abstract]2024 Sep 28;74(1):48. PMID: 39342112 -
J Physiol Sci
Acute effects of empagliflozin on open-loop baroreflex function and urinary glucose excretion in rats with chronic myocardial infarction. [Abstract]2023 Sep 13;73(1):20. PMID: 37704939 -
J Physiol Sci
Acute effects of empagliflozin on open-loop baroreflex function and urine glucose excretion in Goto-Kakizaki diabetic rats. [Abstract]2023 Apr 12;73(1):7. PMID: 37046217 -
Int J Med Sci
Susceptibility to serious skin and subcutaneous tissue disorders and skin tissue distribution of sodium-dependent glucose co-transporter type 2 (SGLT2) inhibitors. [Abstract]2018 Jun 13;15(9):937-943. PMID: 30008607 -
Folia Microbiol (Praha)
Effects of empagliflozin and metformin on biofilm formation and pathogenicity factors of urinary Escherichia coli isolates. [Abstract]2026 Jun 3. PMID: 42234242 -
J Diabetes Complications
Nicotinamide n-methyltransferase inhibitor synergizes with sodium-glucose cotransporter 2 inhibitor to protect renal tubular epithelium in experimental models of type 2 diabetes mellitus. [Abstract]2025 Jan 18;39(2):108952. PMID: 39848127 -
Intensive Care Med Exp
Effects of sodium-glucose transporter-2 inhibition on systemic hemodynamics, renal function, and intra-renal oxygenation in sepsis-associated acute kidney injury. [Abstract]2024 Jul 8;12(1):64. PMID: 38977627 -
Cardiovasc Drugs Ther
Empagliflozin Disrupts a Tnfrsf12a-Mediated Feed Forward Loop That Promotes Left Ventricular Hypertrophy. [Abstract]2022 Aug;36(4):619-632. PMID: 33886003 -
Int J Cardiol Cardiovasc Risk Prev
Empagliflozin modulates microRNA expression in human primary cardiomyocytes under CoCl2-induced hypoxia. [Abstract]2026 Apr 7:29:200632. PMID: 42003872 -
Mol Immunol
Empagliflozin attenuates inflammation levels in autoimmune myocarditis through the STAT3 pathway and macrophage phenotype transformation. [Abstract]2024 Mar:167:43-52. PMID: 38354482 -
Ren Fail
The antioxidative effects of empagliflozin on high glucose‑induced epithelial-mesenchymal transition in peritoneal mesothelial cells via the Nrf2/HO-1 signaling. [Abstract]2022 Dec;44(1):1528-1542. PMID: 36098217 -
Diabetes Metab Syndr Obes
Empagliflozin Regulates the AdipoR1/p-AMPK/p-ACC Pathway to Alleviate Lipid Deposition in Diabetic Nephropathy. [Abstract]2021 Jan 18:14:227-240. PMID: 33500643 -
Diabetes Metab Syndr Obes
Empagliflozin Protects Against Proximal Renal Tubular Cell Injury Induced by High Glucose via Regulation of Hypoxia-Inducible Factor 1-Alpha. [Abstract]2020 Jun 12;13:1953-1967. PMID: 32606855 -
J Chromatogr B Analyt Technol Biomed Life Sci
Development and validation of an LC-MS/MS method for the determination of tofogliflozin in plasma and its application to a pharmacokinetic study in rats. [Abstract]2016 Aug 1:1027:227-33. PMID: 27304784 -
J Chromatogr B Analyt Technol Biomed Life Sci
A quantitative LC-MS/MS method for determining ipragliflozin, a sodium-glucose co-transporter 2 (SGLT-2) inhibitor, and its application to a pharmacokinetic study in rats. [Abstract]2015 Sep 1;1000:22-8. PMID: 26209767 -
Arch Microbiol
Empagliflozin modulates biofilm formation and virulence-associated gene expression in multidrug-resistant Staphylococcus aureus and Acinetobacter baumannii. [Abstract]2026 May 20;208(8):396. PMID: 42159707 -
BMC Cardiovasc Disord
Empagliflozin ameliorates RSL3-induced ferroptosis in vascular endothelial cells via the NRF2/HO-1 pathway. [Abstract]2025 Jun 7;25(1):437. PMID: 40483457 -
Biochem Biophys Res Commun
Empagliflozin reduces renal calcium oxalate deposition in hyperoxaluria rats induced with ethylene glycol-ammonium chloride. [Abstract]2024 Oct 28:737:150912. PMID: 39489113 -
Cell Physiol Biochem
Empagliflozin and Dapagliflozin Reduce ROS Generation and Restore NO Bioavailability in Tumor Necrosis Factor α-Stimulated Human Coronary Arterial Endothelial Cells. [Abstract]2019;53(5):865-886. PMID: 31724838 -
Physiol Rep
Effect of empagliflozin on human primary cardiomyocytes in a chemically induced hypoxia by CoCl2. [Abstract]2025 Dec;13(23):e70653. PMID: 41376177 -
Biomed Chromatogr
A new HPLC-MS/MS method for the simultaneous quantification of SGLT2 inhibitors and metformin in plasma and its application to a pharmacokinetic study in healthy volunteers. [Abstract]2019 Nov;33(11):e4663. PMID: 31339572 -
Biomed Chromatogr
A validated LC-MS/MS method for the determination of canagliflozin, a sodium-glucose co-transporter 2 (SGLT-2) inhibitor, in a lower volume of rat plasma: application to pharmacokinetic studies in rats. [Abstract]2016 Oct;30(10):1549-55. PMID: 26989857 -
-
-
-
bioRxiv
Life in the fast lane: Functional consequences of male-female dynamic differences in the renal autoregulation of flow. [Abstract]2025 Sep 23:2025.09.12.675896. PMID: 41000627 -
-
-
-
-
-
bioRxiv
SGLT2 inhibitors protect against diabetic cardiomyopathy and atrial fibrillation through a CaMKII independent mechanism. [Abstract]2024 Sep 23:2024.09.23.614368. PMID: 39386626 -
-
-
-
-
-
Solvent & Solubility
DMSO : ≥ 200 mg/mL (443.55 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 0.11 mg/mL (0.24 mM; Need ultrasonic and warming)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.61 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (4.61 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 0.5% HPMC in Water
Solubility: 5 mg/mL (11.09 mM); Suspension solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
Mice[2]
Male C57BL/6J mice (10 weeks of age) are used. Empagliflozin is dissolved in hydroxy ethyl cellulose (HEC) and administered to mice in the experimental group (3 or 10 mg/kg) by oral gavage once daily for 8 days, whereas the vehicle group is given same volume of HEC alone.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (279 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
References
[1]. Grempler R, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab. 2012 Jan;14(1):83-90. [Content Brief]
[2]. Cheng ST, et al. The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes. PLoS One. 2016 Jan 25;11(1):e0147391. [Content Brief]
[4]. Sakaeda T, et al. Susceptibility to serious skin and subcutaneous tissue disorders and skin tissue distribution of sodium-dependent glucose co-transporter type 2 (SGLT2) inhibitors. Int J Med Sci. 2018 Jun 13;15(9):937-943. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2177 mL | 11.0887 mL | 22.1774 mL | 55.4434 mL |
| 5 mM | 0.4435 mL | 2.2177 mL | 4.4355 mL | 11.0887 mL | |
| 10 mM | 0.2218 mL | 1.1089 mL | 2.2177 mL | 5.5443 mL | |
| 15 mM | 0.1478 mL | 0.7392 mL | 1.4785 mL | 3.6962 mL | |
| 20 mM | 0.1109 mL | 0.5544 mL | 1.1089 mL | 2.7722 mL | |
| 25 mM | 0.0887 mL | 0.4435 mL | 0.8871 mL | 2.2177 mL | |
| 30 mM | 0.0739 mL | 0.3696 mL | 0.7392 mL | 1.8481 mL | |
| 40 mM | 0.0554 mL | 0.2772 mL | 0.5544 mL | 1.3861 mL | |
| 50 mM | 0.0444 mL | 0.2218 mL | 0.4435 mL | 1.1089 mL | |
| 60 mM | 0.0370 mL | 0.1848 mL | 0.3696 mL | 0.9241 mL | |
| 80 mM | 0.0277 mL | 0.1386 mL | 0.2772 mL | 0.6930 mL | |
| 100 mM | 0.0222 mL | 0.1109 mL | 0.2218 mL | 0.5544 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Empagliflozin Related Classifications
HY-15409 Related Classifications
Powered by Bioz